Biliary Tract Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027A Randomized, Open-label, Phase II Clinical Study of Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine as Adjuvant Therapy for Biliary Tract Cancer.
- Q2 2027A Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract Cancer
- Q2 2027An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
- Q2 2027Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Clinical MilestonesViewHide
- 2026-07-01A Randomized, Open-label, Phase II Clinical Study of Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine as Adjuvant Therapy for Biliary Tract Cancer.Results expected Q1 2027
- 2026-06-26A Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract CancerResults expected Q2 2027
- 2026-06-25An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract MalignanciesResults expected Q2 2027
- 2026-05-19Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 TrialResults expected Q2 2027
- 2026-07-01ClinicalA Randomized, Open-label, Phase II Clinical Study of Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine as Adjuvant Therapy for Biliary Tract Cancer.Results expected Q1 2027
- 2026-06-26ClinicalA Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract CancerResults expected Q2 2027
- 2026-06-25ClinicalAn Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract MalignanciesResults expected Q2 2027
- 2026-05-26ClinicalA Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract CancersResults posted
- 2026-05-19ClinicalMolecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 TrialResults expected Q2 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Biliary Tract Neoplasms2
- Artificial Intelligence1
- Bile Duct Neoplasms1
- Biomarkers, Tumor1
- Cholangiocarcinoma1
- Gallbladder Neoplasms1
- Gastrointestinal Microbiome1
- Immune Checkpoint Inhibitors1
Leading journals6
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- International journal of cancer1
- JAMA oncology1
- Journal for immunotherapy of cancer1
- Journal of the National Comprehensive Cancer Network : JNCCN1
- The Lancet. Oncology1
Leading researchers8
- Kelley RK2
- Abbott DE1
- Abrams T1
- Ahmed A1
- Ahn CH1
- Al-Toubah TE1
- Alese OB1
- Anaya DA1
Affiliations (unnormalised)6
- Yonsei Cancer Center2
- Abramson Cancer Center at the University of Pennsylvania.1
- Asan Medical Center1
- Blacktown Cancer and Haematology Centre1
- Bristol Haematology and Oncology Centre1
- Cancer and Haematology Centre1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Biliary tract neoplasms are tumors or cancers arising in the biliary tract, including the bile ducts and the gallbladder. The term covers malignant disease in these biliary structures.
The supplied grounding indicates that the literature addresses pathology and immunology, but it does not provide a specific biological mechanism for how these tumors develop or progress. Co-studied immune markers include B7-H1 antigen and programmed cell death 1 receptor, suggesting interest in tumor immune interactions.
The grounding supports therapy and drug therapy as major literature themes, but it does not specify particular treatment modalities or drug classes. It also indicates diagnostic and pathological evaluation are commonly covered in the literature.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.